NSB.AU · NeuroScientific Biopharmaceuticals Limited

-

Please sign in to comment on NSB.AU

1 Comment

Admin

4 years, 10 months ago

NeuroScientific Biopharmaceuticals Limited is currently in a long term uptrend where the price is trading 25.5% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

NeuroScientific Biopharmaceuticals Limited's total revenue rose by 1408.2% to $444K since the same quarter in the previous year.

Its net income has increased by 35.2% to $-1M since the same quarter in the previous year.

Finally, its free cash flow grew by 37.3% to $-436K since the same quarter in the previous year.

Based on the above factors, NeuroScientific Biopharmaceuticals Limited gets an overall score of 5/5.

ISIN	AU0000012973
Sector	Healthcare
Industry	Biotechnology
Exchange	AU
CurrencyCode	AUD

PE Ratio	None
Dividend Yield	None
Beta	1.22
Market Cap	43M

ABOUT

NeuroScientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.

NSB.AU · NeuroScientific Biopharmaceuticals Limited

-

NeuroScientific Biopharmaceuticals Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest NeuroScientific Biopharmaceuticals Limited using a moving average strategy